ViaDerma Donates 10,000 Units of VitaStem® to Ukraine
Created by:
Written by Manny Otiko. Edited by Alisa Zaitseva.
Date:
Project Impact
ViaDerma Donates 10,000 Units of VitaStem® to Ukraine — Because Some Missions Can't Wait
ViaDerma, Inc. (OTC: VDRM), a U.S.-based pharmaceutical technology company, has donated 10,000 units of VitaStem®—its FDA-registered OTC topical antibiotic—to Ukrainian medical facilities. The shipment, coordinated with Latvian NGO Brother for Brother Until Victory, crossed the EU border in two deliveries.
Built for crisis conditions
VitaStem® is the world's first product built on the SkinPass™ transdermal drug delivery platform — a patented technology that enables the antibiotic compounds to penetrate significantly deeper into wound tissue than conventional topicals—accelerating healing where time is critical.
Each unit arrived in blue-and-yellow packaging—Ukraine's national colors—with an instructional video allowing soldiers to self-administer as first aid, without doctor’s presence.
It was delivered primarily to frontline hospitals and provided a critical solution for soldiers wounded in combat areas who cannot immediately access medical personnel. The recipients expressed deep gratitude for VitaStem® 's practicality under wartime conditions.
Peteris Bukovskis, Director of AB Wahrung, VitaStem's European distributor and operational lead
The mission behind the mission
The partnership was initiated by Andrew Otiko, Chief Market Acquisition Officer at ViaDerma, who leveraged existing contacts in Ukraine to build the NGO relationship and coordinate delivery logistics.
As a pharmaceutical company founded on the principle of improving global health outcomes, we recognise our responsibility to act during humanitarian crises. We want victims of the war, such as soldiers, to have the care we know VitaStem can provide.
Dr. Christopher Otiko, founder and CEO, podiatric surgeon
A pattern of conviction
Ukraine joins Uganda, Nigeria, Kenya, and the Philippines as recipients of ViaDerma's humanitarian “Project Impact” program—a commitment to advanced care beyond borders and income levels.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM), headquartered in Las Vegas, Nevada, develops the SkinPass™ transdermal platform (U.S. Patent No. 12,465,567, November 2025), achieving higher tissue concentrations than conventional topicals. Flagship product VitaStem® is an FDA-registered OTC topical antibiotic. Founded by Dr. Christopher Otiko, DPM, MS, a podiatric surgeon, researcher, inventor, ViaDerma targets multiple therapeutic categories.
Want to Scale Like This SaaS Startup?
With the right strategy, 65% growth in a year isn’t just possible — it’s repeatable. Let’s uncover the opportunities in your business and build a roadmap to scale with confidence.